Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb beat expectations on both the top and bottom line, with second fiscal quarter 2026 results reported July 30 as revenue rose 5.7% to about $13.0 billion, topping the roughly $11.7 billion consensus by 10.5%, and adjusted EPS of $2.04 beating the $1.60 estimate by 27.5%. Net product sales, the largest line, increased 5.7% to about $12.6 billion, while other revenues climbed 16.6% to about $281 million. Operating income came in at about $4.1 billion, with operating margin near 32%, and net income rose 153.2% to about $3.3 billion from about $1.3 billion a year ago. Adjusted EPS was up 39.7% from $1.46 a year earlier. The company generated operating cash flow of about $4.3 billion and paid about $1.3 billion in dividends. Consensus for the next period calls for EPS of $1.62 on revenue of $12.05 billion.